Endocrine Abstracts

We report a 33 year old female who presented at 23 weeks gestation with rapid onset polyuria and polydipsia. Fluid input and output was approximately 12 litres per day. She denied any other symptoms. She did not have signs of hypopituitarism, Acromegaly or Cushing’s syndrome. Visual fields were normal to confrontation. Her standard glucose tolerance test, Hba1c, creatinine and calcium were normal. Gestational Diabetes Insipidus was (GDI) suspected. Given her pregnancy, a ...

We report a 45-year-old man who developed acquired primary hypoparathyroidism based on a low serum adjusted calcium level and low parathyroid hormone level. His past medical history included recurrent chronic anaemia requiring multiple transfusions since 2011. He was an ex- intravenous drug user, and suffered from chronic bilateral venous leg ulcers, and liver cirrhosis following Hepatitis C infection. Despite using doses of up to 8 mcg Calcitriol daily, his calcium levels fel...

Background: Graves’ disease is widely treated with anti-thyroid medication. After an initial course of treatment, remission is achieved in around 50% of patients. Definitive treatment is generally offered in relapsed cases, based on the assumption that remission rates following a second course of anti-thyroid medication are significantly lower.Method: A database of patients with Graves’ disease has been kept from 2004. 150 patients were suitabl...

Background: Antithyroid drugs (ATDs) are preferred as a first-line treatment for Graves’ disease (GD). However, around 50–60% of patients relapse following treatment withdrawal. Radioactive iodine (RAI) or thyroidectomy is recommended for these patients, however, repeat ATD therapy is a further option, dependent upon patient choice. The long-term efficacy of ATD in relapsed GD has not been robustly established.Methods: We conducted a retrospect...

Background: Current therapeutic options for Graves’ disease (GD) include antithyroid drugs (ATD), radioactive iodine (RAI) or thyroidectomy. ATD treatment is widely used but the relatively high recurrence rate (~50%) after ATD discontinuation is a major concern. Identification of risk factors predicting relapse in GD patients after stopping ATD is decisive to guide initial treatment choices.Methods: We conducted a retrospective study to determine th...